Skip to content

Attorney joins practice group at Goldenberg, Heller & Antognoli, P.C.

Tom Addis has joined the Commercial Practice Group as an associate at the Edwardsville-based law firm of Goldenberg Heller & Antognoli, P.C.

“We’re pleased to welcome Tom to our firm where his transactional experience in real estate, business and commercial law complements our thriving commercial practice group,” said Mark Goldenberg, founder and managing partner of Goldenberg Heller & Antognoli, P.C.

An experienced business advisor and Certified Public Accountant who places a premium on maintaining excellent client communication, Addis’ areas of practice include general business, real estate, general corporate and commercial law, as well as representing financial institutions.

Addis, who served nearly five years in United States Army as a Counterintelligence agent, earned his Juris Doctor in 2006 from Saint Louis University School of Law, Bachelor of Science in Accountancy in 1997 from the University of Missouri-St. Louis, and Bachelor of Science in Finance in 1989 from Missouri State University.

Prior to joining Goldenberg Heller he was in private practice with St. Louis-based law firms, served as a project manager for Union Pacific Railroad, and served as a senior associate in the St. Louis office of a major national accounting firm.

In addition to being a licensed Certified Public Accountant in Missouri, Addis is licensed to practice law in Illinois and Missouri and is a member of the American Bar Association, The Missouri Bar, Bar Association of Metropolitan St. Louis and The Illinois Bar Association.

Goldenberg Heller & Antognoli, P.C., is a full-service law firm serving clients in Illinois and Missouri.  The firm’s practice areas include estate planning, commercial real estate transactions, business and intellectual property transactions, tax controversies, business and commercial litigation, class action litigation, and creditor’s rights. The firm also is well-known in the areas of asbestos litigation, personal injury and pharmaceutical litigation.  More information is available at

Leave a Comment